Literature DB >> 35763125

Insights into the C-terminal domain of apolipoprotein E from chimera studies with apolipophorin III.

James V C Horn1, Leesa M Kakutani1, Vasanthy Narayanaswami1, Paul M M Weers2.   

Abstract

Apolipoprotein E3 (apoE) is a critical cholesterol transport protein in humans and is composed of two domains: a well characterized N-terminal (NT) domain that harbors the low-density lipoprotein LDL receptor, and a less understood C-terminal (CT) domain that is the site of protein oligomerization and initiation of lipid binding. To better understand the domain structure of apoE, the CT domain was fused to apolipophorin III (apoLp-III), a single-domain, monomeric apolipoprotein of insect origin, to yield a chimeric protein, apoLp-III/CT-apoE. Recombinant apoLp-III/CT-apoE maintained an overall helical content similar to that of the parent proteins, while chemical induced unfolding studies indicated that its structural integrity was not compromised. Analysis using 1-anilinonaphthalene-8-sulfonic acid (ANS), a sensitive fluorescent indicator of exposed hydrophobic sites and protein folding, demonstrated that whereas apoLp-III provided few ANS binding sites, apoLp-III/CT-apoE harbored an abundance of ANS binding sites. Thus, this indicated tertiary structure formation in CT-apoE when part of the chimera. Size-exclusion chromatography and chemical crosslinking analysis demonstrated that while apoLp-III is monomeric, the chimeric protein formed large oligomeric complexes, similar to native apoE3. Compared to apoLp-III, the chimera showed a two-fold enhancement in phospholipid vesicle solubilization rates and a significantly improved ability to bind to lipolyzed low-density lipoprotein, preventing the onset of lipoprotein aggregation at concentrations comparable to that of parent CT-apoE. These results confirm that high lipid binding and self-association sites are located in the CT domain of apoE, and that these properties can be transferred to an unrelated apolipoprotein, demonstrating that these properties operate independently from the NT domain.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apolipophorin III; Apolipoprotein E3; Chemical denaturation; Cross linking; Fluorescence; Lipid binding; Lipoproteins; Self-association

Year:  2022        PMID: 35763125     DOI: 10.1007/s11010-022-04497-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

1.  Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain.

Authors:  J A Morrow; M L Segall; S Lund-Katz; M C Phillips; M Knapp; B Rupp; K H Weisgraber
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

Review 2.  Apolipoprotein E structure: insights into function.

Authors:  Danny M Hatters; Clare A Peters-Libeu; Karl H Weisgraber
Journal:  Trends Biochem Sci       Date:  2006-07-03       Impact factor: 13.807

3.  Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4.

Authors:  Masafumi Tanaka; Charulatha Vedhachalam; Takaaki Sakamoto; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

4.  Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model.

Authors:  Hiroyuki Saito; Padmaja Dhanasekaran; David Nguyen; Paul Holvoet; Sissel Lund-Katz; Michael C Phillips
Journal:  J Biol Chem       Date:  2003-04-22       Impact factor: 5.157

Review 5.  Apolipoprotein E isoforms and lipoprotein metabolism.

Authors:  Michael C Phillips
Journal:  IUBMB Life       Date:  2014-09       Impact factor: 3.885

6.  Molecular mechanism of apolipoprotein E binding to lipoprotein particles.

Authors:  David Nguyen; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz
Journal:  Biochemistry       Date:  2009-04-07       Impact factor: 3.162

7.  Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2008-11-18       Impact factor: 5.922

Review 8.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.

Authors:  Guojun Bu
Journal:  Nat Rev Neurosci       Date:  2009-04-02       Impact factor: 34.870

9.  A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein binding and for receptor binding activity.

Authors:  Arun Sivashanmugam; Jianjun Wang
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

Review 10.  Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.

Authors:  Robert W Mahley
Journal:  J Mol Med (Berl)       Date:  2016-06-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.